Xintela AB
1XT
Company Profile
Business description
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Contact
Medicon Village
Lund22381
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Weak investor sentiment for cheap ASX
Earnings growth maintained despite turbulent market conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,016.10 | 57.40 | 0.64% |
| CAC 40 | 8,163.22 | 100.91 | 1.25% |
| DAX 40 | 24,705.16 | 303.46 | 1.24% |
| Dow JONES (US) | 49,298.25 | 356.35 | 0.73% |
| FTSE 100 | 10,362.18 | 143.07 | 1.40% |
| HKSE | 26,132.77 | 234.16 | 0.90% |
| NASDAQ | 25,326.13 | 258.33 | 1.03% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,145.19 | 109.49 | 0.84% |
| S&P 500 | 7,259.22 | 58.47 | 0.81% |
| S&P/ASX 200 | 8,793.60 | 58.60 | 0.67% |
| SSE Composite Index | 4,160.17 | 48.01 | 1.17% |